Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. (April 2016)

• Record Type: Journal Article
• Authors: Maruzzo, Marco; Basso, Umberto; Diminutto, Alberto; Roma, Anna; Zustovich, Fable; Brunello, Antonella; Fiduccia, Pasquale; Banzato, Alberto; Zattoni, Filiberto; Zagonel, Vittorina
• Is Part Of: Future oncology. Volume 12:Number 7(2016)
• Page Start: 909
• Page End: 919
• Publication Date: 2016-04
• Subjects: dose exposure -- neutrophil–lymphocite ratio -- real world -- renal cell carcinoma -- sunitinib -- survival; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.16.14
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014.Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil–lymphocyte ratio <3 was associated both with OS and progression-free survival (50.4 vs 8.4 and 20.0 vs 3.3 months).Conclusion: Sunitinib is active and feasible. Patients receiving <4 full-dose cycles or having increased neutrophil–lymphocyte ratio achieved worse outcomes: therefore, these are present potential predictive factors.